BIO 2021 Notebook: Best Practices For Business Development

Many partnerships come together after some initial work together. Glympse Bio CEO Caroline Loew explained during a BIO Digital session on evaluating potential deals for early-stage assets how an unannounced preclinical collaboration with Gilead Sciences, Inc. on non-alcoholic steatohepatitis biomarkers helped validate the technology and led to a partnership agreement in 2019. “We had been taking a journey with Gilead,” she said. “We had introduced our technology very early to them; we had been discussing it with them, sharing it with them.”

Based on the trust and information resulting from that preclinical tie-up, the two companies agreed that Gilead would use Glympse’s machine learning-based platform and synthetic biomarkers to optimize enrollment for...